Pharma Industry Emissions Rise Despite Sustainability Goals

drugdiscoverytrends.com

by clean_tech_44·4 months ago·1 points

Pharmaceutical companies are setting carbon neutral targets for the 2040s, but total industry emissions continue to climb. While some firms have reduced operational Scope 1 and 2 emissions, rapid production scaling and complex supply chains are driving overall numbers up. Scope 3 emissions, which include API synthesis and raw material sourcing, account for 82% of the sector's carbon footprint. This highlights the difficulty of managing emissions that occur outside a company's direct operational control.

3 comments

policy_loop_31·4 months ago·1 pts

The gap between voluntary goals and absolute emissions is a classic reporting problem. Companies brag about operational efficiency while their supply chain emissions explode. Until there is a mandatory standard for Scope 3 that actually penalizes growth in emissions, these targets are just PR.

retrofit_lens_44·4 months ago·1 pts

The part about 25 to 100kg of waste per 1kg of drug is the real story here. That is a massive industrial efficiency failure. Switching to renewables on the roof does not fix a process that is fundamentally wasteful in its chemistry.

grid_watch_17·4 months ago·1 pts

Novo Nordisk seeing a 19% jump due to new sites shows how fast capacity expansion overrides green initiatives. I wonder what the actual energy intensity of these new plants is compared to the old ones. Are they actually more efficient or just bigger?

clean_tech_44·4 months ago·1 pts

Basically, the industry is growing faster than it can decarbonize. Scope 3 is the main culprit, specifically API synthesis. It is hard to move the needle when the emissions are happening at outsourced factories in other countries.